|Reference : Therapy for Osteoporosis. Miscellaneous and Experimental Agents|
|Scientific journals : Article|
|Human health sciences : Rheumatology|
|Therapy for Osteoporosis. Miscellaneous and Experimental Agents|
|Reginster, Jean-Yves [Université de Liège - ULg > Département des sciences de la santé publique > Epidémiologie et santé publique >]|
|Taquet, A. N. [> > > >]|
|Gosset, Christiane [Université de Liège - ULg > Département des sciences de la santé publique > Santé publique : aspects généraux >]|
|Endocrinology & Metabolism Clinics of North America|
|[en] None of the currently available medications for osteoporosis have demonstrated an ability to fully prevent the occurrence of new vertebral or peripheral osteoporotic fractures once the disease is established. Several new therapies, therefore, are currently being developed to optimize the risk/benefit ratio of osteoporosis treatment. This article discusses a number of treatments currently being considered, including anabolic steroids, growth hormone or insulin-like growth factors, ipriflavone, parathyroid peptides, and strontium. Several other compounds have been suggested recently for treatment of osteoporosis and other are at very early stages of their development. In addition to pharmacologic approaches to the treatment of osteoporosis, hip protectors also may reduce hip fractures.|
There is no file associated with this reference.
All documents in ORBi are protected by a user license.